NYSE:DVA - New York Stock Exchange, Inc. - US23918K1088 - Common Stock - Currency: USD
138.93
+3.96 (+2.93%)
The current stock price of DVA is 138.93 USD. In the past month the price decreased by -7.86%. In the past year, price increased by 4.06%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 12.31 | 91.28B | ||
CVS | CVS HEALTH CORP | 12.1 | 82.77B | ||
DGX | QUEST DIAGNOSTICS INC | 18.89 | 19.37B | ||
LH | LABCORP HOLDINGS INC | 15.38 | 18.75B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 12.71 | 13.87B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 109.42 | 10.53B | ||
CHE | CHEMED CORP | 25.3 | 8.55B | ||
HIMS | HIMS & HERS HEALTH INC | 49.46 | 5.93B | ||
CRVL | CORVEL CORP | 27.43 | 5.89B | ||
GH | GUARDANT HEALTH INC | N/A | 5.63B | ||
OPCH | OPTION CARE HEALTH INC | 26.32 | 5.27B | ||
RDNT | RADNET INC | 77.79 | 3.67B |
DaVita, Inc. engages in the provision of medical care services. The company is headquartered in Denver, Colorado and currently employs 76,000 full-time employees. The firm is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. The company also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
DAVITA INC
2000 16th St
Denver COLORADO 80202 US
CEO: Javier J. Rodriguez
Employees: 70000
Company Website: https://www.davita.com/
Investor Relations: https://investors.davita.com
Phone: 13105362668
The current stock price of DVA is 138.93 USD. The price increased by 2.93% in the last trading session.
The exchange symbol of DAVITA INC is DVA and it is listed on the New York Stock Exchange, Inc. exchange.
DVA stock is listed on the New York Stock Exchange, Inc. exchange.
17 analysts have analysed DVA and the average price target is 168.47 USD. This implies a price increase of 21.26% is expected in the next year compared to the current price of 138.93. Check the DAVITA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DAVITA INC (DVA) has a market capitalization of 11.11B USD. This makes DVA a Large Cap stock.
DAVITA INC (DVA) currently has 70000 employees.
DAVITA INC (DVA) has a support level at 138.92 and a resistance level at 147.74. Check the full technical report for a detailed analysis of DVA support and resistance levels.
The Revenue of DAVITA INC (DVA) is expected to grow by 5.04% in the next year. Check the estimates tab for more information on the DVA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DVA does not pay a dividend.
DAVITA INC (DVA) will report earnings on 2025-05-13, after the market close.
The PE ratio for DAVITA INC (DVA) is 14.62. This is based on the reported non-GAAP earnings per share of 9.5 and the current share price of 138.93 USD. Check the full fundamental report for a full analysis of the valuation metrics for DVA.
The outstanding short interest for DAVITA INC (DVA) is 11.08% of its float. Check the ownership tab for more information on the DVA short interest.
ChartMill assigns a technical rating of 1 / 10 to DVA. When comparing the yearly performance of all stocks, DVA turns out to be only a medium performer in the overall market: it outperformed 41.48% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to DVA. While DVA belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Over the last trailing twelve months DVA reported a non-GAAP Earnings per Share(EPS) of 9.5. The EPS increased by 28.38% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 7.31% | ||
ROA | 5.42% | ||
ROE | 773.06% | ||
Debt/Equity | 75.76 |
ChartMill assigns a Buy % Consensus number of 53% to DVA. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 15.8% and a revenue growth 5.04% for DVA